Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Phosducin-like protein 2 (PDCL2)
- Target
- PDCL2
- Molecular classification
- Chaperonin cofactor / chaperone regulator (specifically cytosolic chaperonin CCT/TRiC complex), Phosducin protein family, Other
01
Overview
Phosducin-like protein 2 (PDCL2) is a conserved eukaryotic cofactor and regulator of the cytosolic chaperonin-containing TCP1 complex (CCT/TRiC). It physically interacts with CCT and modulates its actin, tubulin, and WD-repeat protein folding activity, thereby influencing cytoskeletal assembly and cell cycle progression[1][2]. In mammals, PDCL2 is predominantly expressed in germ cells during spermatogenesis and is required for male fertility; genetic loss in mice leads to infertility due to defective spermiogenesis[2]. Unlike other phosducin-family proteins, PDCL2 does not appear to be critical in G-protein signaling. There are no current therapeutic applications, drug interactions, or established biomarker roles for PDCL2. Its primary biological significance lies in its role as a chaperonin cofactor required for the folding and biogenesis of several essential cellular proteins.
- Other names
- Phosducin-like protein 2PDCL2GCPHLPPhosducin-like protein 2 (mouse, Pdcl2, used in murine biology)PLP2 (less commonly)
02
Mechanism of action
Not applicable; no drugs currently target Phosducin-like protein 2.
03
Biological functions
Modulates cytosolic protein folding (especially actin, tubulin, and WD-repeat proteins)Regulation of the cell cycleEssential for spermiogenesis (male germ cell development)Modulation of cytoskeletal biogenesisDoes *not* play a critical role in canonical heterotrimeric G protein signaling, distinguishing it from related family members
04
Disease associations
Male infertility (essential for spermatogenesis in mice; knockout causes infertility)Other (no substantiated links to cancer, neurodegeneration, or inflammation as of the latest reports)
05
Safety considerations
None reported in clinical context.Mouse knockout studies show complete male infertility without apparently broader systemic toxicity[2].
06
Interacting drugs
None identified; PDCL2 is not a known target of any current approved or investigational drugs[1][2][3][4].
07
Biomarkers
None established for therapeutic or diagnostic use.PDCL2 gene/protein expression may be used as a marker in research on male germ cell development[2].
Beyond the preview
Go deeper on Phosducin-like protein 2 (PDCL2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Phosducin-like protein 2 (PDCL2).